A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis

New England Journal of Medicine

Volumn 342, Issue 11, 2000, Pages 756-762

  Stevens, David A ^a,b,c   Schwartz, Howard J ^h   Lee, Jeannette Y ^h   Moskovitz, Bruce L ^d   Jerome, Dennis C ^e   Catanzaro, Antonino ^c   Bamberger, David M ^h   Weinmann, Allison J ^h   Tuazon, Carmelita U ^f   Judson, Marc A ^h   Platts Mills, Thomas A E ^h   Degraff Jr , Arthur C ^h   Grossman, Jay ^g   Slavin, Raymond G ^h   Reuman, Peter ^c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^f GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^g VIVRA Research   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ITRACONAZOLE; PLACEBO;

ADULT; ARTICLE; BRONCHOPULMONARY ASPERGILLOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

ADRENAL CORTEX HORMONES; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN E; ITRACONAZOLE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0034673751     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200003163421102     Document Type: Article

References (44)

1. McCarthy DS, Simon G, Hargreave FE. The radiological appearances in allergic broncho-pulmonary aspergillosis. Clin Radiol 1970;21:366-75.
2. Hinson KFW, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis: a review and a report of eight new cases. Thorax 1952;7:317-33.
3. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977;86:405-14.
4. Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis: model of bronchopulmonary disease with defined serologic, radiologic, pathologic and clinical findings from asthma to fatal destructive lung disease. Chest 1987;91:Suppl:165S-171S.
5. Basich JE, Graves TS, Baz MN, et al. Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics. J Allergy Clin Immunol 1981;68:98-102.
6. Schwartz HJ, Greenberger PA. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by scrologic and radiologic criteria in patients at risk. J Lab Clin Med 1991;117:138-42.
7. Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994;105:32-6.
8. Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982;96:286-91.
9. Rosenberg M, Patterson R, Roberts M, Wang J. The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis. Am J Med 1978;64:599-606.
10. Safirstein BH, D'Souza MF, Simon G, Tai EHC, Pepys J. Five-year follow-up of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1973;108:450-9.
11. Middleton WG, Paterson IC, Grant IWB, Douglas AC. Asthmatic pulmonary eosinophilia: a review of 65 cases. Br J Dis Chest 1977;71:115-22.
12. Capewell S, Chapman BJ, Alexander F, Greening AP, Crompton GK. Corticosteroid treatment and prognosis in pulmonary eosinophilia. Thorax 1989;44:925-9.
13. Riley DJ, Mackenzie JW, Uhlman WE, Edelman NH. Allergic bronchopulmonary aspergillosis: evidence of limited tissue invasion. Am Rev Respir Dis 1975;111:232-6.
14. Rafferty P, Biggs BA, Crompton GK, Grant IW. What happens to patients with pulmonary aspergilloma? Analysis of 23 cases. Thorax 1983;38: 579-83.
15. Stark JE. Allergic bronchopulmonary aspergillosis successfully treated with inhalations of nystatin: report of a case. Dis Chest 1967;51:96-9.
16. Crompton GK, Milne LJR. Treatment of bronchopulmonary asper gillosis with clotrimazole. Br J Dis Chest 1973;67:301-7.
17. Henderson AH, Pearson JEG. Treatment of bronchopulmonary aspergillosis with observations on the use of natamycin. Thorax 1968;23: 519-23.
18. Currie DC, Lueck C, Milburn HJ, et al. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax 1990; 45:447-50.
19. Slavin RG, Million L, Cherry J. Allergic bronchopulmonary aspergillosis: characterization of antibodies and results of treatment. J Allergy 1970; 46:150-5.
20. Lewiston NJ, Bidermann AA, Harvey B. Allergic bronchopulmonary aspergillosis plus CF: addition of amphotericin B aerosol to therapy. In: Cystic fibrosis: quarterly annotated references. Supplement, 1973 Cystic Fibrosis Club abstracts. Atlanta: National Cystic Fibrosis Research Foundation, 1973:47.
21. Shale DJ, Faux JA, Lane DJ. Trial of ketoconazole in non-invasive pulmonary aspergillosis. Thorax 1987;42:26-31.
22. Fournier EC. Trial of ketoconazole in allergic bronchopulmonary aspergillosis. Thorax 1987;42:831.
23. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992;15:21-34.
24. De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988;31:476-85.
25. Denning DW, Van Wye JE, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991;100:813-9.
26. Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999;115:364-70.
27. Salez F, Brichet A, Desurmont S, et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999;116:1665-8.
28. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31: 103-15.
29. Berlinger FG. Use and misuse of steroids. Postgrad Med 1974;5:153-7.
30. Ganer A, Arathoon E, Stevens DA. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis 1987;9:Suppl 1:S77-S86.
31. Stevens DA, Aristizabal BH. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole. Diagn Microbiol Infect Dis 1997;29:103-6.
32. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800.
33. Stevens DA, Stevens JA. Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods. Diagn Microbiol Infect Dis 1996;26:145-8.
34. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988;26:724-35.
35. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
36. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
37. Title 21, Code of Federal Regulations: investigational new drug, antibiotic, and biologic drug product regulations: treatment, use and sale. Part 312.32. Fed Regist 1987;52:19466-77.
38. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
39. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44. [Erratum, Am J Med 1994;97:497.]
40. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997;157:1857-62.
41. Varis T, Kaukonen K-M, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998;64:363-8.
42. Lebrun-Vignes B, Corbrion-Archer V, Diquet B, et al. Effects of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone in healthy subjects. Exp Clin Pharmacol 1996;18:Suppl B:207. abstract.
43. Lebrun-Vignes B, Chosidow O, Diquet B, et al. Interaction entre itraconazole et corticoidcs (méthylprednisolone et prednisone) chez le sujet sain. Ann Derm Venereol 1997;124:Suppl 1:S53. abstract.
44. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-6.